|
1
|
Bataille R and Harousseau JL: Multiple
myeloma. N Engl J Med. 336:1657–1664. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mahtouk K, Hose D, De VJ, et al: Input of
DNA microarrays to identify novel mechanisms in multiple myeloma
biology and therapeutic applications. Clin Cancer Res.
13:7289–7295. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alexander DD, Mink PJ, Adami HO, et al:
Multiple myeloma: a review of the epidemiologic literature. Int J
Cancer. 120(Suppl 12): 40–61. 2007. View Article : Google Scholar
|
|
4
|
Reece DE: Management of multiple myeloma:
the changing landscape. Blood Rev. 21:301–314. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Richardson PG: A review of the proteasome
inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother.
5:1321–1331. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dimopoulos MA, Beksac M, Benboubker L, et
al: Phase II study of bortezomib-dexamethasone alone or with added
cyclophosphamide or lenalidomide for sub-optimal response as
second-line treatment for patients with multiple myeloma.
Haematologica. 98:1264–1272. 2013. View Article : Google Scholar
|
|
7
|
Kastritis E, Palumbo A and Dimopoulos MA:
Treatment of relapsed/refractory multiple myeloma. Semin Hematol.
46:143–157. 2009. View Article : Google Scholar
|
|
8
|
Gordon S, Akopyan G, Garban H and Bonavida
B: Transcription factor YY1: structure, function, and therapeutic
implications in cancer biology. Oncogene. 25:1125–1142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baritaki S, Sifakis S, Huerta-Yepez S, et
al: Overexpression of VEGF and TGF-β1 mRNA in Pap smears correlates
with progression of cervical intraepithelial neoplasia to cancer:
Implication of YY1 in cervical tumorigenesis and HPV infection. Int
J Oncol. 31:69–79. 2007.
|
|
10
|
Seligson D, Horvath S, Huerta-Yepez S, et
al: Expression of transcription factor Yin Yang 1 in prostate
cancer. Int J Oncol. 27:131–141. 2005.PubMed/NCBI
|
|
11
|
Begon DY, Delacroix L, Vernimmen D,
Jackers P and Winkler R: Yin Yang 1 cooperates with activator
protein 2 to stimulate ERBB2 gene expression in mammary cancer
cells. J Biol Chem. 280:24428–24434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brankin B, Skaar TC, Brotzman M, Trock B
and Clarke R: Autoantibodies to the nuclear phosphoprotein
nucleophosmin in breast cancer patients. Cancer Epidemiol
Biomarkers Prev. 7:1109–1115. 1998.PubMed/NCBI
|
|
13
|
Erkeland SJ, Valkhof M,
Heijmans-Antonissen C, et al: The gene encoding the transcriptional
regulator Yin Yang 1 (YY1) is a myeloid transforming gene
interfering with neutrophilic differentiation. Blood.
101:1111–1117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vega MI, Huerta-Yepez S, Jazirehi AR,
Garban H and Bonavida B: Rituximab (chimeric anti-CD20) sensitizes
B-NHL cell lines to Fas-induced apoptosis. Oncogene. 24:8114–8127.
2005.PubMed/NCBI
|
|
15
|
Vega MI, Jazirehi AR, Huerta-Yepez S and
Bonavida B: Rituximab-induced inhibition of YY1 and Bcl-xL
expression in Ramos non-Hodgkin’s lymphoma cell line via inhibition
of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance
and chemoresistance, respectively. J Immunol. 175:2174–2183.
2005.PubMed/NCBI
|
|
16
|
Baritaki S, Huerta-Yepez S, Sakai T,
Spandidos DA and Bonavida B: Chemotherapeutic drugs sensitize
cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and
inhibition of Yin Yang 1. Mol Cancer Ther. 6:1387–1399. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Durie BG: Staging and kinetics of multiple
myeloma. Semin Oncol. 13:300–309. 1986.PubMed/NCBI
|
|
18
|
Rajkumar SV, Harousseau JL, Durie B, et
al: Consensus recommendations for the uniform reporting of clinical
trials: report of the International Myeloma Workshop Consensus
Panel 1. Blood. 117:4691–4695. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huerta-Yepez S, Vega M, Jazirehi A, et al:
Nitric oxide sensitizes prostate carcinoma cell lines to
TRAIL-mediated apoptosis via inactivation of NF-kappa B and
inhibition of Bcl-xl expression. Oncogene. 23:4993–5003. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vega MI, Huerta-Yepez S, Martinez-Paniagua
M, et al: Rituximab-mediated cell signaling and
chemo/immuno-sensitization of drug-resistant B-NHL is independent
of its Fc functions. Clin Cancer Res. 15:6582–6594. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huerta-Yepez S, Vega M, Escoto-Chavez SE,
et al: Nitric oxide sensitizes tumor cells to TRAIL-induced
apoptosis via inhibition of the DR5 transcription repressor Yin
Yang 1. Nitric Oxide. 20:39–52. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhan F, Hardin J, Kordsmeier B, et al:
Global gene expression profiling of multiple myeloma, monoclonal
gammopathy of undetermined significance, and normal bone marrow
plasma cells. Blood. 99:1745–1757. 2002. View Article : Google Scholar
|
|
23
|
Zhan F, Barlogie B, Arzoumanian V, et al:
Gene-expression signature of benign monoclonal gammopathy evident
in multiple myeloma is linked to good prognosis. Blood.
109:1692–1700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garban HJ and Bonavida B: Nitric oxide
inhibits the transcription repressor Yin-Yang 1 binding activity at
the silencer region of the Fas promoter: a pivotal role for nitric
oxide in the up-regulation of Fas gene expression in human tumor
cells. J Immunol. 167:75–81. 2001. View Article : Google Scholar
|
|
25
|
Huerta-Yepez S, Baritaki S, Baay-Guzman G,
et al: Contribution of either YY1 or BclxL-induced inhibition by
the NO-donor DETANONOate in the reversal of drug resistance, both
in vitro and in vivo. YY1 and BclXL are overexpressed in prostate
cancer. Nitric Oxide. 29:17–24. 2013. View Article : Google Scholar
|
|
26
|
Liu H, Schmidt-Supprian M, Shi Y, et al:
Yin Yang 1 is a critical regulator of B-cell development. Genes
Dev. 21:1179–1189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sakhinia E, Glennie C, Hoyland JA, et al:
Clinical quantitation of diagnostic and predictive gene expression
levels in follicular and diffuse large B-cell lymphoma by RT-PCR
gene expression profiling. Blood. 109:3922–3928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Naidoo K, Clay V, Hoyland JA, et al: YY1
expression predicts favourable outcome in follicular lymphoma. J
Clin Pathol. 64:125–129. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Castellano G, Torrisi E, Ligresti G, et
al: Yin Yang 1 overexpression in diffuse large B-cell lymphoma is
associated with B-cell transformation and tumor progression. Cell
Cycle. 9:557–563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Allouche A, Nolens G, Tancredi A, et al:
The combined immunodetection of AP-2alpha and YY1 transcription
factors is associated with ERBB2 gene overexpression in primary
breast tumors. Breast Cancer Res. 10:R92008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
De Nigris F, Rossiello R, Schiano C, et
al: Deletion of Yin Yang 1 protein in osteosarcoma cells on cell
invasion and CXCR4/angiogenesis and metastasis. Cancer Res.
68:1797–1808. 2008.PubMed/NCBI
|
|
32
|
Berchuck A, Iversen ES, Lancaster JM, et
al: Patterns of gene expression that characterize long-term
survival in advanced stage serous ovarian cancers. Clin Cancer Res.
11:3686–3696. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chinnappan D, Xiao D, Ratnasari A, Andry
C, King TC and Weber HC: Transcription factor YY1 expression in
human gastrointestinal cancer cells. Int J Oncol. 34:1417–1423.
2009.PubMed/NCBI
|
|
34
|
Matsumura N, Huang Z, Baba T, et al: Yin
Yang 1 modulates taxane response in epithelial ovarian cancer. Mol
Cancer Res. 7:210–220. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Q, Stovall DB, Inoue K and Sui G:
The oncogenic role of Yin Yang 1. Crit Rev Oncog. 16:163–197. 2011.
View Article : Google Scholar
|
|
36
|
Kim JD, Yu S and Kim J: YY1 is
autoregulated through its own DNA-binding sites. BMC Mol Biol.
10:852009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang H, Hertlein E, Bakkar N, et al:
NF-kappaB regulation of YY1 inhibits skeletal myogenesis through
transcriptional silencing of myofibrillar genes. Mol Cell Biol.
27:4374–4387. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Flanagan JR: Autologous stimulation of YY1
transcription factor expression: role of an insulin-like growth
factor. Cell Growth Differ. 6:185–190. 1995.PubMed/NCBI
|
|
39
|
Li Y, Wang F, Xu J, et al: Progressive
miRNA expression profiles in cervical carcinogenesis and
identification of HPV-related target genes for miR-29. J Pathol.
224:484–495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Petrella BL and Brinckerhoff CE: PTEN
suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null
renal-cell carcinoma. Cancer Biol Ther. 8:1389–1401. 2009.
View Article : Google Scholar : PubMed/NCBI
|
